SCHEMBL3352875

SCHEMBL3352875

Cc1cc(C(N)=O)cc(C(=O)NC(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.49
TAS1R1 Q7RTX1 2/20 0.49
PARP1 P09874 1/20 0.43
SCN5A Q14524 1/20 0.42
MLYCD O95822 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
ALOX5 P09917 1/20 0.39
ATM Q13315 1/20 0.39
ALDH1A1 P00352 4/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP2C19 P33261 1/20 0.38
PTGS2 P35354 1/20 0.38
ALOX12 P18054 1/20 0.38
TP53 P04637 2/20 0.37
BRD4 O60885 1/20 0.37
CREBBP Q92793 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26454584 0.91 TAS1R3 (0.56) TAS1R3TAS1R1MLYCDNPSR1MAPT
SCHEMBL14275080 0.87 TAS1R3 (0.60) TAS1R3TAS1R1MLYCDNPSR1MAPT
SCHEMBL6173135 0.84 TPMT (0.57) TAS1R3TAS1R1MLYCDNPSR1MAPT
SCHEMBL4443226 0.82 MLYCD (0.53) TAS1R3TAS1R1MLYCDNPSR1MAPT
SCHEMBL12688285 0.82 TAS1R3 (0.53) TAS1R3TAS1R1SCN5AMLYCDNPSR1
Acetic Acid SCHEMBL11295237 0.81 TAS1R3 (0.55) TAS1R3TAS1R1MLYCDNPSR1MAPT
SCHEMBL6120857 0.80 BCL2L1 (0.42) SCN5AMLYCDNPSR1HPGDALOX5
SCHEMBL12865158 0.80 PARP1 (0.60) PARP1MAPTHPGDALDH1A1CYP2C19
SCHEMBL2789109 0.80 NPSR1 (0.61) TAS1R3TAS1R1SCN5AMLYCDNPSR1
SCHEMBL2977147 0.79 NPSR1 (0.59) PARP1NPSR1HPGDATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-20070213407-A1 Compounds to treat Alzheimer's disease ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC 2007-09-13 US disclosed
US-7214715-B2 Compounds to treat Alzheimer's disease PHARMACIA & UPJOHN (US) 2007-05-08 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213407-A1 Compounds to treat Alzheimer's disease PSEN2, PSEN1, CHAT TAS1R3 3294/4885TAS1R1 3249/4885PARP1 3392/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP TAS1R3 3334/4885TAS1R1 3324/4885PARP1 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.